Healthcare

A collection of 1 post

Why Eli Lilly's New Pill Could Decide the Obesity Drug War

Lilly's oral GLP-1 Foundayo just launched into a $200B+ market where it already holds 60% share. Here's what the competition — and the investment case — looks like now.

Operated by veterans. Driven by discipline. Built for the early mover.
AlphaBriefing provides financial commentary and market analysis for informational purposes only. We do not offer personalized investment advice. All content is opinion-based and should not be considered a recommendation to buy or sell any security. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal. Individual results may vary. We value your privacy. Any data collected is used to improve your experience and to provide relevant updates about our services.
©2025 AlphaBriefing. All rights reserved. | Privacy Policy | Legal Disclaimer